Diabetes drug tested as potential weapon against opioid addiction
NCT ID NCT06639464
Summary
This study is testing if semaglutide, a medication currently used for diabetes and weight loss, can help people with opioid addiction. It will involve 46 adults who are already taking buprenorphine treatment. Participants will receive weekly injections of either semaglutide or a placebo for 12 weeks to see if it reduces drug cravings and helps prevent relapse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.